NDA 020870 · Noven Pharms INC
Combipatch
Estradiol, Norethindrone Acetate · Transdermal · Estrogen
Last checked: Nov 20, 2026Latest source record: Feb 15, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1998
Aug 7, 1998
Approved uses
1
Original approval plus efficacy supplements
Registered trials
1,701
351 Phase 3, 176 recruiting
FAERS reports
28
7 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: CARDIOVASCULAR DISORDERS, BREAST CANCER, ENDOMETRIAL CANCER, AND PROBABLE DEMENTIA Estrogen Plus Progestin Therapy Cardiovascular Disorders and Probable Dementia Estrogen plus progestin therapy should not be used for the prevention of cardiovascular disease or dementia. (See CLINICAL STUDIES and WARNINGS , Cardiovascular Disorders and Probable Dementia ). The Women’s Health Initiative (WHI) estrogen plus progestin substudy reported an increased risk of deep vein thrombosis (DVT), pulmonary embolism (PE), stroke and myocardial infarction (MI) in postmenopausal women (50 to 79 years of age) during 5.6 years of treatment with daily oral conjugated estrogens (CE) [0.625 mg] combined with medroxyprogesterone acetate (MPA) [2.5 mg], relative to placebo. (See CLINICAL STUDIES and WARNINGS , Cardiovascular Disorders ). The WHI Memory Study (WHIMS) estrogen plus progestin ancillary...
What it is approved for
From the label in effect Nov 10, 2026.
INDICATIONS AND USAGE CombiPatch is indicated in a woman with a uterus for: Treatment of moderate to severe vasomotor symptoms due to menopause. Treatment of moderate to severe symptoms of vulvar and vaginal atrophy due to menopause. When prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered. Treatment of hypoestrogenism due to hypogonadism, castration, or primary ovarian failure.
Therapeutic areas: Endocrinology and women's health
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
2 products under this application
- COMBIPATCH · ESTRADIOL 0.05MG/24HR; NORETHINDRONE ACETATE 0.14MG/24HR · FILM, EXTENDED RELEASE, TRANSDERMAL · Prescription
- COMBIPATCH · ESTRADIOL 0.05MG/24HR; NORETHINDRONE ACETATE 0.25MG/24HR · FILM, EXTENDED RELEASE, TRANSDERMAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Estradiol" as an intervention, any sponsor and status, largest first.
- Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug EfficacyPivotal-lookingActive, not recruiting
Medical Research CouncilGovernment (non-federal)
NCT00268476 · 11,992 participants · Start Jul 8, 2005 · Primary completion Mar 2026
Drug: Celecoxib; Docetaxel and 7 more · For: Prostate Cancer
Sites: Lausanne, Switzerland; Winterthur, Switzerland; Chur, Switzerland · 120 sites in all
- Short-term Effects of Transdermal Estradiol on Female COVID-19 PatientsPivotal-lookingCompleted
Istanbul University - CerrahpasaAcademic, hospital or other
NCT05774405 · 9,169 participants · Start Jul 1, 2020 · Primary completion Jul 31, 2021
Drug: Climara 0.1Mg/24Hr Transdermal System · For: COVID-19; Hormone Replacement Therapy
Sites: Istanbul, Turkey (Türkiye)
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)NIH
NCT00006324 · 6,360 participants · Start Dec 1999
Drug: Ethinyl estradiol/levonorgestrel; Medroxyprogesterone acetate · For: HIV Infections
Sites: Research Triangle Park, North Carolina
- A Study to Evaluate the Efficacy and Safety of DR-103 for the Prevention of PregnancyPivotal-lookingCompleted
Teva Women's HealthTeva (TEVA)
NCT00996580 · 3,597 participants · Start Oct 2009 · Primary completion Sep 2011
Drug: DR-103 · For: Pregnancy Prevention
Sites: Montgomery, Alabama; Phoenix, Arizona; Tucson, Arizona · 94 sites in all
- Study of the Contraceptive Efficacy and Safety of a NOMAC-E2 Combined Oral Contraceptive (COC)(P06448)Pivotal-lookingTerminated
Organon and CoIndustry
NCT01656434 · 3,173 participants · Start Nov 2, 2012 · Primary completion Feb 12, 2014
Drug: NOMAC-E2; NETA-EE and 2 more · For: Contraception
- Contraceptive Efficacy and Safety of NOMAC-E2 Combined Oral ContraceptivePivotal-lookingTerminated
Organon and CoIndustry
NCT05264506 · 3,055 participants · Start Feb 17, 2022 · Primary completion Jan 12, 2024
Drug: NOMAC-E2 COC · For: Contraception
Sites: Birmingham, Alabama; Dothan, Alabama; Mobile, Alabama · 103 sites in all
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening TrialPivotal-lookingRecruiting
National Cancer Institute (NCI)NIH
NCT05564377 · 2,900 participants (planned) · Start Apr 7, 2023 · Primary completion Jul 1, 2030
Drug: Alpelisib; Binimetinib and 13 more · For: Advanced Malignant Solid Neoplasm; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8 and 12 more
Sites: Birmingham, Alabama; Mobile, Alabama; Anchorage, Alaska · 484 sites in all
- A Study to Evaluate the Efficacy and Safety of DR-102 for the Prevention of PregnancyPivotal-lookingCompleted
Teva Branded Pharmaceutical Products R&D, Inc.Teva (TEVA)
NCT01178125 · 2,858 participants · Start Aug 2010 · Primary completion Jan 2013
Drug: DR-102 · For: Contraception; Female Contraception
Sites: Montgomery, Alabama; Phoenix, Arizona; Little Rock, Arkansas · 62 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- application site pruritus7
- product adhesion issue7
- application site erythema6
- application site irritation5
- application site inflammation3
- application site rash3
- drug delivery system issue3
- invasive ductal breast carcinoma3
- no adverse event3
- abdominal discomfort2
- application site discolouration2
- application site reaction2
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2014 | 1 |
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 3 |
| 2020 | 1 |
| 2021 | 1 |
| 2023 | 3 |
| 2024 | 1 |
| 2025 | 2 |
| 2026 | 14 |
Recalls
2 FDA enforcement reports for this application.
Jul 30, 2021 · Class II · Ongoing
Failed Stability Specifications; out of specification for shear.
Jul 30, 2021 · Class II · Ongoing
Failed Stability Specifications; out of specification for shear.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Combipatch (Estradiol/Norethindrone Acet)
2024 spending
$5.4M
Beneficiaries
3,709
13,387 claims
Per beneficiary
$1,443
$29.89 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $3,411,638 |
| 2021 | $3,921,844 |
| 2022 | $4,218,918 |
| 2023 | $4,681,878 |
| 2024 | $5,351,119 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- A systematic review and meta-analysis of venous thrombosis risk among users of combined oral contraception.
Dragoman MV, Tepper NK, Fu R, et al. · Int J Gynaecol Obstet 2018 · Meta-Analysis, Systematic Review
- Effect of Soy Isoflavones on Measures of Estrogenicity: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Viscardi G, Back S, Ahmed A, et al. · Adv Nutr 2025 · Systematic Review, Meta-Analysis
- Systematic Review and Meta-analysis: Changes of Gut Microbiota before and after Menopause.
Yang M, Wen S, Zhang J, et al. · Dis Markers 2022 · Meta-Analysis, Systematic Review
- Vascular Effects of Early versus Late Postmenopausal Treatment with Estradiol.
Hodis HN, Mack WJ, Henderson VW, et al. · N Engl J Med 2016 · Comparative Study, Randomized Controlled Trial
- Pharmacological Treatments for Menopausal Vasomotor Symptoms: A Systematic Review and Bayesian Network Meta-Analysis of Efficacy and Safety.
Oliveira Amador WF, Saraiva CA, Ruelas MG, et al. · Eur J Obstet Gynecol Reprod Biol 2025 · Network Meta-Analysis, Systematic Review
- The Effect of Sex Hormones on Joint Ligament Properties: A Systematic Review and Meta-analysis.
Gilmer G, Crasta N, Tanaka MJ · Am J Sports Med 2025 · Systematic Review, Meta-Analysis
Sponsor: Noven Pharms INC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.